TY - JOUR
T1 - Serum FAM19A5 levels
T2 - A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder
AU - Han, Kyu Man
AU - Tae, Woo Suk
AU - Kim, Aram
AU - Kang, Youbin
AU - Kang, Wooyoung
AU - Kang, June
AU - Kim, Yong Ku
AU - Kim, Bongcheol
AU - Seong, Jae Young
AU - Ham, Byung Joo
PY - 2020/7
Y1 - 2020/7
N2 - Chronic low-grade inflammation contributes to the pathophysiology of major depressive disorder (MDD). This study aimed to examine the association between serum levels of FAM19A5, a novel chemokine-like peptide that reflects reactive astrogliosis and inflammatory activation in the brain, and the neurodegenerative changes of MDD by investigating the correlation between serum FAM19A5 levels and cortical thickness changes in patients with MDD. We included 52 drug-naïve patients with MDD and 60 healthy controls (HCs). Serum FAM19A5 levels were determined in peripheral venous blood samples using a sandwich enzyme-linked immunosorbent assay. All participants underwent T1-weighted structural magnetic resonance imaging. Serum FAM19A5 levels were greater in patients with MDD than in HCs. In the MDD group, there were significant inverse correlations between serum FAM19A5 levels and cortical thickness in the prefrontal regions (i.e., the left inferior and right medial superior frontal gyri), left posterior cingulate gyrus, right cuneus, and both precunei, which showed significantly reduced thickness in patients with MDD compared to HCs. However, no correlation between serum FAM19A5 level and cortical thickness was observed in the HC group. The results of our study indicate that serum FAM19A5 levels may reflect reactive astrogliosis and related neuroinflammation in MDD. Our findings also suggest that serum FAM19A5 may be a potential biomarker for the neurodegenerative changes of MDD.
AB - Chronic low-grade inflammation contributes to the pathophysiology of major depressive disorder (MDD). This study aimed to examine the association between serum levels of FAM19A5, a novel chemokine-like peptide that reflects reactive astrogliosis and inflammatory activation in the brain, and the neurodegenerative changes of MDD by investigating the correlation between serum FAM19A5 levels and cortical thickness changes in patients with MDD. We included 52 drug-naïve patients with MDD and 60 healthy controls (HCs). Serum FAM19A5 levels were determined in peripheral venous blood samples using a sandwich enzyme-linked immunosorbent assay. All participants underwent T1-weighted structural magnetic resonance imaging. Serum FAM19A5 levels were greater in patients with MDD than in HCs. In the MDD group, there were significant inverse correlations between serum FAM19A5 levels and cortical thickness in the prefrontal regions (i.e., the left inferior and right medial superior frontal gyri), left posterior cingulate gyrus, right cuneus, and both precunei, which showed significantly reduced thickness in patients with MDD compared to HCs. However, no correlation between serum FAM19A5 level and cortical thickness was observed in the HC group. The results of our study indicate that serum FAM19A5 levels may reflect reactive astrogliosis and related neuroinflammation in MDD. Our findings also suggest that serum FAM19A5 may be a potential biomarker for the neurodegenerative changes of MDD.
KW - Astrocyte
KW - Biomarker
KW - Cortical thickness
KW - Depression
KW - FAM19A5
KW - Inflammation
KW - Magnetic resonance imaging
KW - Major depressive disorder
KW - Reactive astrogliosis
UR - http://www.scopus.com/inward/record.url?scp=85082534413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082534413&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2020.03.021
DO - 10.1016/j.bbi.2020.03.021
M3 - Article
C2 - 32217080
AN - SCOPUS:85082534413
VL - 87
SP - 852
EP - 859
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
SN - 0889-1591
ER -